Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
OMB showed better persistence and adherence compared with platform self-injectable DMTs, as well as better persistence compared with oral DMTs. This real-world analysis provides additional insights into OMB utilization among patients with MS in clinical practice and demonstrates that OMB is a valuable treatment option for these patients.
Authors
- Chi‐Chang Chen (ORCID: https://orcid.org/0000-0002-7065-9607)
- Rifat Tuly (ORCID: https://orcid.org/0000-0002-8437-6034)
- Y. T. Gu (ORCID: https://orcid.org/0000-0002-9648-4913)
- Brandon Brown
- Qiujun Shao (ORCID: https://orcid.org/0000-0003-1920-5500)
- Carrie M. Hersh (ORCID: https://orcid.org/0000-0002-5716-5645)
- Magdaliz Gorritz (ORCID: https://orcid.org/0000-0001-6806-3188)
- Abhijit Gadkari
Institutions
- Lou Ruvo Brain Institute (US)
- IQVIA (United States) (US)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.msard.2024.105888
- Citations
- 6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.55
Funders
- Novartis Pharmaceuticals Corporation